Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis

Cancer

Volumn 106, Issue 7, 2006, Pages 1489-1497

  Tsukamoto, Toshihiko ^a   Iida, Juri ^a   Dobashi, Yoh ^b   Furukawa, Taiji ^c   Konishi, Fumio ^d  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Jichi Omiya Medical Center   (Japan)

Author keywords

Ceroid lipofuscinosis, neuronal 1 (CLN1); Ceroid lipofuscinosis, neuronal 2 (CLN2); Colorectal carcinoma; Metastasis

Indexed keywords

CATHEPSIN B; CATHEPSIN D; CATHEPSIN H; CATHEPSIN L; CLN1 ENZYME; CLN2 ENZYME; LYSOSOME ENZYME; MESSENGER RNA; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE ISOLATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR CLONING; NEURONAL CEROID LIPOFUSCINOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSINS; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33645830071     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21764     Document Type: Article

References (34)

1. Berdowska I. Cysteine proteases as disease markers. Clin Chim Acta. 2004;342:41-69.
2. Journet A, Ferro M. The potentials of MS-based subproteomic approaches in medical science: the case of lysosomes and breast cancer. Mass Spectrom Rev. 2004;23:393-442.
3. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004;10:39-49.
4. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69-89.
5. Sheahan K, Shuja S, Murnane MJ. Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 1989;49:3809-3814.
6. Shuja S, Sheahan K, Murnane MJ. Cysteine endopeptidase activity levels in normal human tissues, colorectal adenomas and carcinomas. Int J Cancer. 1991;49:341-346.
7. Murnane MJ, Sheahan K, Ozdemirli M, Shuja S. Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res. 1991;51:1137-1142.
8. Campo E, Munoz J, Miquel R, et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol. 1994;145:253-2562.
9. Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Peyrat JP. Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Cancer Lett. 1995;96:267-275.
10. Murnane MJ, Shuja S, del Re E, Cai J, Iacobuzio-Donahue C, Klepeis V. Characterizing human colorectal carcinomas by proteolytic profile. In Vivo. 1997;11:209-216.
11. Iacobuzio-Donahue CA, Shuja S, Cai J, Peng P, Murnane MJ. Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression. J Biol Chem. 1997;14;272:29190-29199.
12. Herszenyi L, Plebani M, Carraro P, et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 1999;86:1135-1142.
13. Hirai K, Yokoyama M, Asano G, Tanaka S. Expression of cathepsin B and cystatin C in human colorectal cancer. Hum Pathol. 1999;30:680-686.
14. del Re EC, Shuja S, Cai J, Murnane MJ. Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas. Br J Cancer. 2000;82:1317-1326.
15. Kanber Y, Demirbag NR, Sam, AD, Aydin N. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers. 2002;17:165-168.
16. Talieri M, Papadopoulou S, Scorilas A, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett. 2004;205:97-106.
17. Troy AM, Sheahan K, Mulcahy HE, Duffy MJ, Hyland JM, O'Donoghue DP. Expression of cathepsin B and L antigen and activity is associated with early colorectal cancer progression. Eur J Cancer. 2004;40:1610-1616.
18. Sis B, Sagol O, Kupelioglu A, et al. Prognostic significance of matrix metalloprotease-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract. 2004;200:379-387.
19. Sleat DE, Donnelly RJ, Lackland H, et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science. 1997;277:1802-1805.
20. Wisniewski KE. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology. 2001;57:576-581.
21. Mole SE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol. 2004;14:70-76.
22. Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature. 1995;376:584-587.
23. The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell. 1995;82:949-957.
24. Tyynela J, Sohar I, Sleat DE, et al. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 2000;19:2786-2792.
25. Junaid MA, Clark GM, Pullarkat RK. A lysosomal pepstatin-insensitive protease as a novel biomarker for breast carcinoma. Int J Biol Markers. 2000;152:129-134.
26. Rylova SN, Amalfitano A, Persaud-Sawin DA, et al. The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 2002;62:801-808.
27. Cho S, Dawson G. Palmitoyl protein thioesterase 1 protects against apoptosis mediated by Ras-Akt-caspase pathway in neuroblastoma cells. J Neurochem. 2000;74:1478-1488.
28. Dawson G, Dawson, SA, Marinzi C, Dawson PE. Anti-tumor promoting effects of palmitoyl: protein thioesterase inhibitors against a human neurotumor cell line. Cancer Lett. 2002;187:163-168.
29. Ezaki J, Takeda-Ezaki M, Oda K, Kominami E. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun. 2000;268:904-908.
30. McDonald JK, Hoisington, AR, Eisenhauer DA. Partial purification and characterization of an ovarian tripeptidyl peptidase: a lysosomal exopeptidase that sequentially releases collagen-related (Gly-Pro-X) triplets. Biochem Biophys Res Commun. 1985;126:63-71.
31. Page AE, Fuller K, Chambers TJ, Warburton MJ. Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption. Arch Biochem Biophys. 1993;306:354-359.
32. Ezaki J, Takeda-Ezaki M, Kominami E. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. J Biochem. 2000;128:509-516.
33. Kopan S, Sivasubramaniam U, Warburton MJ. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. Biochem Biophys Res Commun. 2004;319:58-65.
34. Lin L, Sohar I, Lackland H, Lobel P. The human CLN2 protein/tripeptidyl- peptidase I is a serine protease that autoactivates at acidic pH. J Biol Chem. 2001;276:2249-2255.